Is it necessary to take Riboxil/Calilon for three consecutive years?

Ribociclib/Calilon (Ribociclib) is widely used because of its representativeness among CDK4/6 inhibitors. Many patients will have questions when receiving treatment: Do they need to be taken continuously for three years to achieve curative effect? In fact, treatment time is not a rigid number, but needs to be comprehensively decided based on the patient's individual situation, changes in condition, and the doctor's follow-up recommendations.

Reboxiclib is mainly used for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, and is usually used in combination with endocrine therapy drugs. It is designed to control disease progression in the long term rather than as a short-term shock treatment.

Because breast cancer is a chronic disease that requires long-term management, it often takes months or even years for patients to experience stable clinical benefits when taking reboxil. Therefore, international guidelines emphasize the principle of "continuous use until the disease progresses or the patient cannot tolerate it", but do not clearly stipulate that it must be used continuously for three years.

In some cases, if the patient responds well to the drug and the side effects are controllable, the doctor may recommend that the patient maintain the drug for a long time, even for more than three years, which can delay the recurrence or progression of the disease. However, if the patient becomes intolerable due to hematological adverse reactions, liver function abnormalities, or electrocardiogram changes during treatment, the doctor may also consider adjusting the dose or discontinuing the drug in stages instead of blindly requiring a fixed course of treatment.

It is worth noting that patients cannot interrupt or shorten the treatment cycle at will. Because the efficacy ofCDK4/6 inhibitors relies on continuous inhibition of cancer cell proliferation, once the drug is stopped at will, it may cause tumor cells to become active again, thus affecting the overall efficacy. On the contrary, if patients follow the doctor's recommendations for regular monitoring and dose adjustment as needed, they can not only maintain the efficacy but also reduce the risk of side effects.

Reference materials:https://us.kisqali.com/